Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003387 · ClinicalTrials.gov registry record · Phase 3

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

A Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
366
Enrollment target
20
Study locations

NCT00003387: Completed Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

NCT00003387 is a Phase 3 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 366 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003387, a Phase 3 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
366 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effective than combined chemotherapy and radiation therapy alone in treating patients with non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel followed by radiation therapy and chemotherapy with radiation therapy and chemotherapy alone in treating patients with stage III non-small cell lung cancer that cannot be removed during surgery.

Conditions Studied

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel
  • RADIATION radiation therapy
  • DRUG chemotherapy

Study Locations (20)

California

  • University of California San Diego Cancer Center - La Jolla
  • Veterans Affairs Medical Center - San Francisco - San Francisco
  • UCSF Cancer Center and Cancer Research Institute - San Francisco

Illinois

  • University of Illinois at Chicago Health Sciences Center - Chicago
  • Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
  • University of Chicago Cancer Research Center - Chicago

District of Columbia

  • Howard University Cancer Center - Washington D.C.
  • Walter Reed Army Medical Center - Washington D.C.

Iowa

  • Hematology Oncology Associates of the Quad Cities - Bettendorf
  • Holden Comprehensive Cancer Center at The University of Iowa - Iowa City

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • University of Massachusetts Memorial Medical Center - Worcester

Missouri

  • Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
  • Ellis Fischel Cancer Center - Columbia - Columbia

Alabama

  • Veterans Affairs Medical Center - Birmingham - Birmingham

Delaware

  • CCOP - Christiana Care Health Services - Wilmington

Trial Details

FieldValue
Enrollment Target 366 participants
Start Date 1998-07
Est. Completion 2009-04
Phase Phase 3

What the finished NCT00003387 record still lists

NCT00003387 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.

NCT00003387 names 20 study sites across 12 states, led by California, Illinois, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00003387 about?

NCT00003387 is a clinical study titled "Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effectiv...

What is the current status of trial NCT00003387?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 1998-07. Estimated completion is 2009-04.

What conditions does trial NCT00003387 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00003387?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), chemotherapy (DRUG).

Who is sponsoring clinical trial NCT00003387?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003387 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003387's enrollment target sits among peer trials

366 85th of 409 higher than 325 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05083481 · 366 participants · Phase 1

    A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

  • NCT05429632 · 366 participants · Phase 3

    Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • NCT06979453 · 366 participants · Phase 3

    A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  • NCT04049604 · 365 participants · NA

    IDENTIFY Study: Natural History of Maternal Neoplasia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003387, the US trial registry maintained by the National Library of Medicine. NCT00003387 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.